Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BNT142 (BioNTech SE)
- Development stage
- Phase 1
- Lead developer
- BioNTech
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
BNT142 is an investigational messenger RNA (mRNA) vaccine developed by BioNTech that targets fibroblast activation protein alpha (FAP). FAP is a cell-surface serine protease highly expressed on cancer-associated fibroblasts (CAFs), which play a crucial role in promoting tumor growth, immunosuppression, and metastasis within the tumor microenvironment. By delivering mRNA encoding FAP, the vaccine aims to induce a robust T-cell-mediated immune response against CAFs, thereby disrupting the supportive tumor stroma and enhancing the efficacy of other immunotherapies. BNT142 is formulated in lipid nanoparticles (LNPs) for systemic administration and is currently being evaluated in Phase 1/2 clinical trials for patients with advanced solid tumors.
- Other names
- fibroblast activation protein messenger ribonucleic acid vaccineFAP mRNA vaccineFAP-FixVac
02
Targets
FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on BNT142 (BioNTech SE).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BNT142 (BioNTech SE).